Tech Company Financing Transactions
Blueprint Medicines Funding Round
On 1/7/2014, Blueprint Medicines announced $25 million in Series B funding from Nextech Invest, Casdin Capital and F-Prime Capital.
Transaction Overview
Company Name
Announced On
1/7/2014
Transaction Type
Venture Equity
Amount
$25,000,000
Round
Series B
Investors
Nextech Invest (Lead Investor) (Thilo Schroeder)
Third Rock Ventures (Alexis Borisy)
Proceeds Purpose
Blueprint's lead programs include the first known selective inhibitors of the KIT D816V mutation, which is the genomic driver of the underserved systemic mastocystosis patient population, as well as a key genomically defined subset of patients with gastrointestinal stromal tumors (GIST). The Company's pipeline also includes the first known isoform-selective FGFR4 inhibitors for patients with hepatocellular carcinoma with FGF19 amplification, the first clear genomic driver in liver cancer, and other tumors. Blueprint expects to initiate clinical trials for these programs in 2015.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
45 Sidney St. 200
Cambridge, MA 02139
USA
Cambridge, MA 02139
USA
Phone
Website
Email Address
Overview
Blueprint Medicines discovers and develops highly selective kinase inhibitors for patients with genomically defined cancers.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Jeffery Albers
Chief Medical Officer
Anthony Boral
Chief Scientific Officer
Marion Dorsch
Executive Vice President
Christoph Lengauer
VP - Bus. Development
Kate Haviland
VP - Finance
Michael Landsittel
VP - General Counsel
Tracey McCain
VP - Human Resources
Debbie Durso-Bumpus
VP - Operations
Christopher Murray
Browse more venture capital transactions:
Prev: 1/7/2014: Onit venture capital transaction
Next: 1/7/2014: BioMedomics venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. VC investment data records reported here come from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs